BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, September 23, 2023
Home » Blogs » BioWorld MedTech Perspectives » FDA's resource dilemma: does more money equal more regulatory mischief?

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech / CDRH / FDA

FDA's resource dilemma: does more money equal more regulatory mischief?

Sep. 23, 2011
By Mark McCarty
No Comments

Much has been made of the slow-down in device approvals at FDA's Center for Devices and Radiological Health, and the explanations range from a preoccupation with scientific and statistical minutia to a paranoia that yet another incident will subject the agency to another lashing in the court of public opinion.

But let's face it, FDA gets some pretty shabby treatment on Capitol Hill, too. I recall a hearing in which then-Senator Hillary Clinton (D-New York) grilled incoming FDA commissioner Andrew von Eschenbach, MD, like a common criminal. She and Sen. Patty Murray (D-Washington) never allowed von Eschenbach to completely answer a question. It was like an interrogation from a movie about the KGB, and it was an embarrassment.

It hasn't been that bad for FDA on the Hill lately, but the media never miss a chance to hammer the agency. If FDA approves a drug that has a problem that didn't emerge in a clinical trial, it's FDA's fault. The explanation in the mainstream media is never “you can't demand drug makers enroll a million patients in a trial.” The explanation is always malfeasance by industry or just plain stupidity at FDA.

On the other end of things, FDA is accused of stonewalling if it doesn't approve things quickly enough, and patient groups are almost as bad as industry on this score. Again, there are instances in which I think the reviewers at the Office of Device Evaluation (ODE) blew it, but some of the criticism is nothing short of nuts.

A point I like to bring up in conversation is that FDA's resources have been known to be deficient for decades, and one idea that sometimes bubbles to the surface in such chats is that more cash at FDA means more regulatory overkill. That thought has occurred to me, but I'm starting to wonder.

After all, one way to beat someone into paranoia at work is to heap more and more work on them and take away resources, and then treat them like criminals in the nation's media every time something goes wrong. And when it comes to medicine, something is bound to go wrong sooner or later, isn't it?

Would a fully loaded checking account fix what's ailing FDA? Not in the short term, and the Cult of Thalidomide might never work its way out of the agency. I'm also not recommending that industry roll over on the user fee issue. Still, anyone who thinks that starving FDA into submission on device applications is a reasonable approach is forgetting one thing: It's already been tried.

As Dr. Phil might say, “how's that working for you?”

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 22, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 22, 2023.
  • Hands holding torn contract

    Quite a fix: Orthofix sacks three top execs

    BioWorld MedTech
    Orthofix Medical Inc. terminated its CEO, chief financial officer and chief legal officer in a move that plunged the stock from $18.63 at Monday’s close to $13.01...
  • Illustration of Alzheimer’s in the brain.

    Study identifies cause of death for Alzheimer’s neurons

    BioWorld
    By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...
  • New NLRP3 inflammasome inhibitors named in PTC Therapeutics patent

    BioWorld Science
    PTC Therapeutics Inc. has patented new NLRP3 inflammasome inhibitors reported to be useful...
BioFuture ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing